Mind-Body Program for Cancer Patients

This study is currently recruiting participants.

Verified by Albert Einstein College of Medicine of Yeshiva University, September 2005

Sponsors and Collaborators:	Albert Einstein College of Medicine of Yeshiva University American Cancer Society
Information provided by:	Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier:	NCT00179387

Purpose

The purpose of this study is to find out if Mind-Body groups can help improve the physical and emotional well-being of people facing cancer or its treatment.

Condition	Intervention
Neoplasms	Behavioral: Mind-Body Psychotherapy Group

MedlinePlus related topics: Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Educational/Counseling/Training, Randomized, Single Blind, Uncontrolled, Parallel Assignment
Official Title:	Evaluation of Mind-Body Groups on the Quality of Life of Cancer Patients

Further study details as provided by Albert Einstein College of Medicine of Yeshiva University:

Estimated Enrollment:	140
Study Start Date:	December 2004

Detailed Description:

Pain, fatigue, anxiety, depression, nausea, sexual impairment, body image disturbance, relationship strains, existential distress and role losses are all potential “side-effects” of living with cancer and its treatment. Behavioral interventions have shown some success in mitigating distress and QOL impairment among cancer patients. The purpose of this randomized-controlled study is to compare the effects of Mind-body group interventions on the quality of life of patients with advanced cancer. Patients are randomized to one of two psychotherapy groups, which occur weekly for eight weeks. Quality of life assessments are conducted at baseline and two and four-month intervals.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Current Diagnosis of Breast Cancer Stage IV, Colorectal Cancer, Stage IV, or any other type of Cancer, stage III or IV
Language is English or Spanish

Exclusion Criteria:

Patient is currently attending other support/psychotherapy group
Significant Cognitive Impairment
ECOG performance status = 3 or 4
Current major untreated psychiatric disorder
Unable to attend intervention in following 8 weeks due to medical or practical restrictions

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00179387

Contacts

Contact: Alyson Moadel, Ph.D.

718-430-2696

moadel@aecom.yu.edu

Locations

United States, New York
Albert Einstein College of Medicine	Recruiting
Bronx, New York, United States, 10461
Contact: Alyson Moadel, Ph.D. 718-430-2696 moadel@aecom.yu.edu
Principal Investigator: Alyson Moadel, Ph.D.

Sponsors and Collaborators

Albert Einstein College of Medicine of Yeshiva University

American Cancer Society

Investigators

Principal Investigator:

Alyson Moadel, Ph.D.

Albert Einstein College of Medicine of Yeshiva University

More Information

Study ID Numbers:	TURSG-03-190-01-PBP
Study First Received:	September 13, 2005
Last Updated:	September 13, 2005
ClinicalTrials.gov Identifier:	NCT00179387
Health Authority:	United States: Institutional Review Board

Keywords provided by Albert Einstein College of Medicine of Yeshiva University:

Neoplasms
Needs Assessment
Adaptation Psychological
Minority Groups

Psychotherapy, Group
Program Evaluation
Spirituality
Spiritual Therapies

Study placed in the following topic categories:

Quality of Life

Additional relevant MeSH terms:

Neoplasms

ClinicalTrials.gov processed this record on January 14, 2009